Juno Therapeutics, Inc. , a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced, in partnership with its collaborators, early clinical data from two oral presentations for two product candidates at the American Association for Cancer Research Annual Meeting 2016 in New Orleans, Louisiana. JCAR018 is a chimeric antigen receptor T cell product candidate targeting CD22, and had data from a Phase I trial in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia .